Skip to main content
. 2002 Jul 22;2002(3):CD003642. doi: 10.1002/14651858.CD003642.pub2

Comparison 2. Herbal medicines versus hypoglycemic drugs.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Normalisation of fasting blood glucose levels (< 7.2 mmol/L) 17   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
1.1 Bushen Jiangtang Tang versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Composite Trichosanthis versus tolbutamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Jiangtang Kang granule versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Jiangtang No. 1‐3 capsule versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Jinqi Jiangtang capsule versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Kelening versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Ketangling versus gliclazide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Maziren Wan versus glibenclamide plus phenformin 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Shenqi Jiangtang Yin versus tolbutamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Shenqi Yuxiao Tang versus gliclazide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Shengqing Jiangtang recipe versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.12 Shugan Huoxue recipe versus gliclazide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.13 Shuizhi Sanhuang Tang versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.14 Tangning Pian versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.15 Xiaoke Ling capsule versus gliclazide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.16 Xiaoke Tang versus glibenclamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.17 Xiaoke Yin versus glibenclamide plus Insoral 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.18 Yishen Huoxue Tiaogan versus gliclazide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.19 Yuquan Wan versus tolbutamide 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fasting blood glucose levels (mmol/L) 21   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Bushen Jiangtang Tang versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Jianpi Jiangtang Tang versus gliclazide plus alginric sodium diester 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Jiangtang Kang granule versus glibenclamide (end of 60 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Jiangtang Kang granule versus glibenclamide (end of 180 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Jiangtang No. 1‐3 capsule versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Jinqi Jiangtang capsule versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Kelening versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Maziren Wan versus glibenclamide plus phenformin 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Potentilla chinensis plus berberine versus metformin plus glipizide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Shenqi Jiangtang Yin versus tolbutamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Shenqi Yuxiao Tang versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Shengqing Jiangtang recipe versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Shugan Huoxue recipe versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Shuizhi Sanhuang Tang versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Tangfu Kang versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Tangning Pian versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Tangzhi Xiao versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.18 Tianyuan Jiangtang Wan versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.19 Xiaoke Ling capsule versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.20 Xiaoyao San versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.21 Yiqi Yangyin Huayu Tang versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.22 Yiqi Yangyin Huoxue recipe versus glurenorm 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.23 Yishen Huoxue Tiaogan versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Glycated haemoglobin levels (%) 6   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Jiangtang Kang granule versus glibenclamide (end of 60 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Jiangtang Kang granule versus glibenclamide (end of 180 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Kelening versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Tangfu Kang versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Tangning Pian versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Tianyuan Jiangtang Wan versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Xiaoyao San versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Fasting serum insulin levels (mU/L) 4   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Jiangtang Kang granule versus glibenclamide (end of 60 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Jiangtang Kang granule versus glibenclamide (end of 180 days) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Kelening versus glibenclamide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Tangfu Kang versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Tangzhi Xiao versus gliclazide 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]